Article Text

Download PDFPDF

Lung-targeting lentiviral vector for passive immunisation against influenza
  1. Tiong Kit Tan1,
  2. Toby P E Gamlen1,
  3. Pramila Rijal2,
  4. Alain R Townsend2,
  5. Deborah R Gill3,4,
  6. Stephen C Hyde3,4
  1. 1Radcliffe Department of Medicine, Gene Medicine Research Group, Nuffield Division of Clinical Laboratory Science, Oxford, UK
  2. 2Radcliffe Department of Medicine, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK
  3. 3Gene Medicine Research Group, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, Oxford University, Oxford, UK
  4. 4UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK
  1. Correspondence to Dr Stephen C Hyde, Gene Medicine Research Group, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; steve.hyde{at}ndcls.ox.ac.uk

Abstract

When recombinant simian immunodeficiency virus (SIV) is pseudotyped with the F and HN glycoproteins from murine respiratory Sendai virus (rSIV.F/HN), it provides efficient lung cell targeting and lifelong transgene expression in the murine airways. We have shown that a single dose of rSIV.F/HN can direct stable expression of neutralising antibody against influenza in the murine airways and systemic circulation, and protects mice against two different influenza strains in lethal challenge experiments. These data suggest that rSIV.F/HN could be used as a vector for passive immunisation against influenza and other respiratory pathogens.

  • viral infection
  • respiratory infection
  • infection control
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors TKT performed all the experiments in Figures 1 and 2. TPEG assisted in the experiment in Figure 3. PR and ART advised on the influenza challenge experiments and produced the influenza viruses in the challenge studies. DRG and SCH oversaw the studies. All authors reviewed and provided comments on the final draft of the manuscript.

  • Funding This work was funded by a King’s Scholarship awarded to TKT by the Government of Malaysia, and by a Wellcome Trust Portfolio Award to DRG and SCH.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.